The Effects of Compulsory Licensing on Innovation and Access to Health Care
1 November 2000
By Dr. Richard Rozek
Many developing countries are enacting and implementing laws to protect intellectual property rights ("IPRs"). The debate is whether to allow compulsory or involuntary licensing of pharmaceutical patents within the emerging IPR regimes to control costs, protect local industries or improve access to health care. In fact, compulsory licensing acts as a negative force on the ability of a country to grow, reduces the incentive for firms to develop and disseminate medicines and inhibits access to health care.
Dr. Richard P. Rozek addresses these issues in this paper, published in the Journal of World Intellectual Property, Volume 3, No. 6, November 2000, pp. 889-917.
A reprint of this article is available from the author upon request.
